Превосходство агомелатина в сравнении с флуоксетином в антидепрессивной эффективности у пациентов с тяжелым бдр: рандомизированное двойное-слепое исследование




Скачать 341.72 Kb.
страница3/3
Дата13.08.2016
Размер341.72 Kb.
1   2   3

Конфликт интересов

Данное исследование проводилось при поддержке компании Сервье. Авторы получали от Сервье гонорары и/или исследовательские гранты. Кроме заявленных выше авторы не имеют никаких других значимых профессиональных или финансовых отношений с какими либо организациями, конфликтующих с предметом и материалами данной публикации.


Список литературы

American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amosse C, et al. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367:553-561.

Bertaina-Anglade V, Drieu La RC, Boyer PA, Mocaer E (2006). Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17:703-713.

Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.

Committee for Proprietary Medicinal Products (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. CPMP/EWP/518/97. Available at: www.emea.europa.eu/pdfs/human/ewp/ 051897en.pdf. [Accessed 18 December 2009]

Dubocovich ML (2006). Drug evaluation: agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs 7:670-680.

Emens J, Lewy A, Kinzie JM, Arntz D, Rough J (2009). Circadian misalignment in major depressive disorder. PsychiatryRes 168:259-261.

European Medicines Agency (2009). European Public Assessment Report. Valdoxan. Available at: http://www.emea.europa.eu/humandocs/Humans/ EPAR/valdoxan/valdoxan.htm. [Accessed 4 December 2009]

Fuchs E, Schmelting B, Mocaer E (2006). Effects of the novel antidepressant agomelatine (S20098) and fluoxetine in chronically stressed tree shrews,an animal model of depression. Eur Neuropsychopharmacol 16:S338-S339.

Goodwin GM, Emsley R, Rembry S, Rouillon F (2009). Agomelatine prevents relapse in patients with major depressive disorder, without evidence of discontinuation syndrome. J Clin Psychiatry 70:1128-1137.

Guy W (1976). ECDEU assessment manual for psychopharmacology. Revision ed. US Department of Health, Education, and Welfare (ADM) 756-338. Rockville, MD: National Institute of Mental Health.

Hamilton M (1959). A rating scale for anxiety. J Neurol Neurosurg Psychiatry 23:56-62.

Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415-426.

Kasper S, Hajak G, Wulff K, Hoogendijk WI, Montejo AL, Smeraldi E, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 71:109-120.

Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100.

Kennedy SH, Rizvi SJ (2010). Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 24:479-499.

Khan A, Warner HA, Brown WA (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317.

Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002). The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 5:1-14.

Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A (1997). Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 272:R1178-R1188.

Lemoine P, Guilleminault C, Alvarez E (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomi­zed, double-blind comparison with venlafaxine. J Clin Psychiatry 68:1723-1732.

Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, Van Cauter E, Copinschi G (2005). Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 63:298-304.

Loo H, Hale A, D haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.

Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008). A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623-627.

Millan MJ, Brocco M, Gobert A, Dekeyne A (2005). Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic proper­ties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 177:448-458.

Montgomery SA, Lecrubier Y (1999). Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9:259-264.

Montgomery SA, Kasper S (2007). Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283-291.

Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280.

Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329.

Nemeroff CB, Thase ME (2007). A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41 :351-359.

Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry63:424-434.

Ohayon MM, Roth T (2003). Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 37:9-15.

Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673.

Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechan­isms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227.

Papp M, Gruca P, Boyer PA, Mocaer E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694-703.

Peeters F, Berkhof J, Delespaul P, Rottenberg J, Nicolson NA (2006). Diurnal mood variation in major depressive disorder. Emotion 6:383-391.

Quera Salva MA, Vanier B, Laredo J, Hartlety S, Chapotot F, Moulin C, et al. (2007). Major depressive disorder, sleep EEG, and agomelatine: an open-label study. Int J Neuropsychopharmacol 10:691-696.

Reynolds JEF, editor (1996). Martindale, the extra pharmacopoeia. 31st ed. London, UK: Royal Pharmaceutical Society.

Ruhe HG, Dekker JJ, Peen J, Holman R, de Jonghe F (2005). Clinical use of the Hamilton depression rating scale: is increased efficiency possible? A post hoc comparison of Hamilton depression rating scale, Maier and Bech subscales, Clinical global impression, and symptom checklist-90 scores. ComprPsychiatry 46:417-427.

Santen G, Gomeni R, Danhof M, Pasqua OD (2008). Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 42:1000-1009.

Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, , Bonora LI, et al. (1997). The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232-241.

Souetre E, Salvati E, Belugou JL, Pringuey D, Candito M, Krebs B, et al. (1989). Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. PsychiatryRes 28:263-278.

Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, et al. (2009). Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34:2390-2403.

Spalletta G, Pasini A, Caltagirone C (2002). Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. J Clin Psychopharmacol 22:263-266.

Stephenson DA, Harris B, Davies RH, Mullin JM, Richardson E, Boardman H, et al. (2000). The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Hum Psychopharmacol 15:529-534.

Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, et al. (1992). Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 35:1484-1486.





1   2   3


База данных защищена авторским правом ©uverenniy.ru 2016
обратиться к администрации

    Главная страница